117 related articles for article (PubMed ID: 18268396)
1. Pretreatment with interferon-alpha2a modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Klatte T; Ittenson A; Röhl FW; Ecke M; Allhoff EP; Böhm M
Onkologie; 2008 Feb; 31(1-2):28-34. PubMed ID: 18268396
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract][Full Text] [Related]
3. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.
Klatte T; Ittenson A; Röhl FW; Ecke M; Allhoff EP; Böhm M
Br J Cancer; 2006 Nov; 95(9):1167-73. PubMed ID: 17031403
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Eur Urol; 2002 Apr; 41(4):458-67; discussion 467-8. PubMed ID: 12074819
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Schmitt E; Gertenbach U; Fornara P; Heynemann H; Maskow A; Ecke M; Wöltjen HH; Jentsch H; Wieland W; Wandert T; Reitz M;
Br J Cancer; 2005 Mar; 92(5):843-6. PubMed ID: 15756254
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
8. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
10. Complex perioperative immuno-dysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Philipp C; Röhl FW; Ansorge S; Allhoff EP
J Urol; 2001 Sep; 166(3):831-6. PubMed ID: 11490228
[TBL] [Abstract][Full Text] [Related]
11. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
Hernberg M; Muhonen T; Pyrhönen S
Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
[TBL] [Abstract][Full Text] [Related]
12. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
13. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
14. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
[TBL] [Abstract][Full Text] [Related]
15. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
[TBL] [Abstract][Full Text] [Related]
16. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
[TBL] [Abstract][Full Text] [Related]
17. [Perioperative immune modulation in renal cell carcinoma--review of the current situation].
Böhm M; Klatte T; Allhoff EP
Aktuelle Urol; 2003 Sep; 34(5):319-27. PubMed ID: 14566659
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Thompson J; Gurney H; Selby P; Figlin R; Negrier S; Ernst S; Siebels M; Ginsberg M; Rittweger K; Hooftman L
Ann Oncol; 2002 Nov; 13(11):1799-805. PubMed ID: 12419754
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
